On June 15, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that its abstract has been accepted for oral virtual presentation at the 3rd Annual Next Gen Immuno-Oncology Congress, which takes place from 25-26 June 2020 (Press release, BerGenBio, JUN 15, 2020, View Source [SID1234561099]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation to be given by Prof. Hani Gabra MD PhD, CMO BerGenBio, will provide an update of results from a phase II trial (BGBC008), evaluating bemcentinib in combination with MSD’s Keytruda (pembrolizumab) in previously treated non-small cell lung cancer (NSCLC) patients with confirmed progression, including positive top line clinical and translational data from stage 1 of Cohort B in patients having failed prior immune checkpoint therapy.
The presentation will be available on the Company website in the Presentations section on 25 June: www.bergenbio.com/investors/presentations/
Title: Targeting AXL to leverage checkpoint immunotherapy: Updated results of the BGBC008 phase II study of bemcentinib and pembrolizumab in recurrent NSCLC
Date and time: 25 June 2020, 10am EST
Session name: Targeted Antibodies and Cellular Therapy
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body’s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.